The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://kianagvkq052542.nytechwiki.com/29514/glp_3_retatrutide_a_comparative_analysis